Association between acetaminophen use and vitiligo in US women and men.
acetaminophen
epidemiology
prospective study
vitiligo
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
30
05
2023
received:
18
08
2022
accepted:
21
08
2023
medline:
10
11
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
ppublish
Résumé
Exposure to chemical phenols, which can act as tyrosine analogues and result in anti-melanocyte autoimmunity, has been associated with vitiligo. Acetaminophen (N-acetyl-p-aminophenol) is an over-the-counter analgesic of phenolic origin. The risk of vitiligo with systemic exposure to acetaminophen has not yet been evaluated. We examined the risk of vitiligo with regular use acetaminophen in women, the Nurses' Health Study (NHS) and in men, the Health Professionals Follow-up Study (HPFS). Regular acetaminophen use was asked biennially from 1990 in NHS and from 1986 in HPFS, and the year of clinician-diagnosed vitiligo was asked retrospectively in 2012 in the cohorts. In NHS, a total of 161 vitiligo cases were identified during a follow-up of 571,724 person-years; in HPFS, a total of 183 vitiligo cases were identified during a follow-up of 680,313 person-years. Regular use of acetaminophen was associated with an increased vitiligo risk in NHS but not HPFS. The multivariable relative risk (RR) was 1.52 (95% confidence interval [CI] 1.03-2.25) in NHS and 1.09 (95% CI 0.76-1.55) in HPFS. The higher risk of vitiligo was similar by duration of acetaminophen use in women; the multivariable RRs were 1.47 (95% CI 0.98-2.21) for acetaminophen use under 5 years, and 1.78 (95% CI 1.11-2.84) for acetaminophen use over 5 years. Acetaminophen may be associated with a higher risk of vitiligo in women.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Exposure to chemical phenols, which can act as tyrosine analogues and result in anti-melanocyte autoimmunity, has been associated with vitiligo. Acetaminophen (N-acetyl-p-aminophenol) is an over-the-counter analgesic of phenolic origin. The risk of vitiligo with systemic exposure to acetaminophen has not yet been evaluated.
METHODS
METHODS
We examined the risk of vitiligo with regular use acetaminophen in women, the Nurses' Health Study (NHS) and in men, the Health Professionals Follow-up Study (HPFS). Regular acetaminophen use was asked biennially from 1990 in NHS and from 1986 in HPFS, and the year of clinician-diagnosed vitiligo was asked retrospectively in 2012 in the cohorts.
RESULTS
RESULTS
In NHS, a total of 161 vitiligo cases were identified during a follow-up of 571,724 person-years; in HPFS, a total of 183 vitiligo cases were identified during a follow-up of 680,313 person-years. Regular use of acetaminophen was associated with an increased vitiligo risk in NHS but not HPFS. The multivariable relative risk (RR) was 1.52 (95% confidence interval [CI] 1.03-2.25) in NHS and 1.09 (95% CI 0.76-1.55) in HPFS. The higher risk of vitiligo was similar by duration of acetaminophen use in women; the multivariable RRs were 1.47 (95% CI 0.98-2.21) for acetaminophen use under 5 years, and 1.78 (95% CI 1.11-2.84) for acetaminophen use over 5 years.
CONCLUSIONS
CONCLUSIONS
Acetaminophen may be associated with a higher risk of vitiligo in women.
Substances chimiques
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e348-e351Subventions
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2023 Australasian College of Dermatologists.
Références
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. https://doi.org/10.1016/S0140-6736(14)60763-7
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-214. https://doi.org/10.1034/j.1600-0749.2003.00032.x
Dunlap R, Wu S, Wilmer E, Cho E, Li WQ, Lajevardi N, et al. Pigmentation traits, sun exposure, and risk of incident vitiligo in women. J Invest Dermatol. 2017;137(6):1234-1239. https://doi.org/10.1016/j.jid.2017.02.004
van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011;131(6):1240-1251. https://doi.org/10.1038/jid.2011.16
Harris JE. Chemical-induced vitiligo. Dermatol Clin. 2017;35(2):151-161. https://doi.org/10.1016/j.det.2016.11.006
Sasaki M, Kondo M, Sato K, Umeda M, Kawabata K, Takahashi Y, et al. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism. Pigment Cell Melanoma Res. 2014;27(5):754-763. https://doi.org/10.1111/pcmr.12269
Wu SW, Li WQ, Cho EY, Harris JE, Speizer F, Qureshi AA. Use of permanent hair dyes and risk of vitiligo in women. Pigm Cell Melanoma R. 2015;28(6):744-746. https://doi.org/10.1111/pcmr.12402
Brancaccio R, Cohen DE. Contact leukoderma secondary to para-phenylenediamine. Contact Dermatitis. 1995;32(5):313. https://doi.org/10.1111/j.1600-0536.1995.tb00795.x
Trattner A, David M. Hair-dye-induced contact vitiligo treated by phototherapy. Contact Dermatitis. 2007;56(2):115-116. https://doi.org/10.1111/j.1600-0536.2007.00989.x
Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011;171(16):1487-1493. https://doi.org/10.1001/archinternmed.2011.356